Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Development Sciences : Cutting-Edge Development

Biologics Development Sciences: We Enable Cutting-Edge Development

The Biologics Development Sciences department supports the discovery of biological new molecular entities (NMEs), advises on preclinical toxicology programs and collaborates at each stage of development to translate basic scientific research and pharmacology into a thorough understanding of the effects of our biologics and biopharmaceutical therapeutic agents in patients. To ensure effective development and assessment of biologics, this group applies in-depth expertise in the immunogenicity of biologics, its assessment and consequences, while also evaluating the pharmacokinetics and pharmacodynamics relationships found in early data in order to predict the most accurate dosing regimens for future testing. 

Through the design and conduct of preclinical studies, early and late phases, and postmarketing clinical trials, Biologics Development Sciences assesses the biochemical, pharmacological and clinical effects of biologics development candidates and assists in the submission of regulatory applications and post-marketing studies. Our support has helped to drive the development and approval of multiple blockbuster biologic therapies, with many more exciting new treatments and biological platforms in the pipeline.




Retina image